Reflux Disease and Barrett’s Esophagus

Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal disorders. The key feature of GERD is reflux of gastric contents into the esophagus. Medical treatment with proton-pump inhibitors (PPIs) is well established and is considered the standard treatment. Given the high prevalence of the condition and the excellent response to medical therapy, antireflux surgery is an option for patients with volume reflux that is not properly controlled by medical therapy. Adenocarcinoma is a rare but life-threatening complication of GERD. The only known precursor lesion for esophageal adenocarcinoma is Barrett's esophagus. In recent years, a clearer understanding of the development of Barrett's and of its progression toward invasive cancer has developed. Genetic factors almost certainly determine the individual risk. The length of the Barrett's esophagus segment and the size of a hiatal hernia are associated with the risk of developing high-grade dysplasia and esophageal adenocarcinoma.
With regard to the clinical management of GERD patients with Barrett's, endoscopic surveillance at 3-year intervals is now considered appropriate in the absence of dysplasia. In patients with high-grade dyspepsia, the situation is more difficult. While a considerable proportion of these patients may already have invasive cancers, there is also the possibility that there is only focal dysplasia. For this reason, it is justifiable to carry out curative endoscopic resection. Mucosal ablation procedures may also be appropriate, but these still need to be properly investigated in clinical trials.

References

• 1 Bollschweiler E, Wolfgarten E, Gutschow C, Holscher A H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.  Cancer. 2001;  92 549-555
• 2 Avidan B, Sonnenberg A, Giblovich H, Sontag S J. Reflux symptoms are associated with psychiatric disease.  Aliment Pharmacol Ther. 2001;  15 1907-1912
• 3 Colombo P, Mangano M, Bianchi P A, Penagini R. Effect of calories and fat on postprandial gastro-oesophageal reflux.  Scand J Gastroenterol. 2002;  37 3-5
• 4 Romero Y, Cameron A J, Schaid D J. et al . Barrett’s esophagus: prevalence in symptomatic relatives.  Am J Gastroenterol. 2002;  97 1127-1132
• 5 Fackler W K, Ours T M, Vaezi M F, Richter J E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.  Gastroenterology. 2002;  122 625-632
• 6 Richter J E. H. pylori: the bug is not all bad.  Gut. 2001;  49 319-320
• 7 Koike T, Ohara S, Sekine H. et al . Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis.  Aliment Pharmacol Ther. 2001;  15 813-820
• 8 Moayyedi P, Bardhan C, Young L. et al . Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.  Gastroenterology. 2001;  121 1120-1126
• 9 Sonnenberg A. What to do about Helicobacter pylori? A decision analysis of its implication on public health.  Helicobacter. 2002;  7 60-66
• 10 Wu J C, Chan F K, Wong S K. et al . Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.  Aliment Pharmacol Ther. 2002;  16 545-552
• 11 Hurenkamp G J, Grundmeijer H G, van der EA . et al . Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study.  Aliment Pharmacol Ther. 2001;  15 1047-1054
• 12 Goldblum J R, Richter J E, Vaezi M. et al . Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa.  Am J Gastroenterol. 2002;  97 302-311
• 13 Castell D O, Vela M. Combined multichannel intraluminal impedance and pH-metry: an evolving technique to measure type and proximal extent of gastroesophageal reflux.  Am J Med. 2001;  111 (Suppl 8A) 157S-159S
• 14 Edwards S J, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.  Aliment Pharmacol Ther. 2001;  15 1729-1736
• 15 Zhang Q, Lehmann A, Rigda R. et al . Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease.  Gut. 2002;  50 19-24
• 16 Katz P O. Lessons learned from intragastric pH monitoring.  J Clin Gastroenterol. 2001;  33 107-113
• 17 Lundell L, Miettinen P, Myrvold H E. et al . Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.  J Am Coll Surg. 2001;  192 172-179
• 18 Frazzoni M, Grisendi A, Lanzani A. et al . Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease: a pH-metric comparison.  Dig Liver Dis. 2002;  34 99-104
• 19 Spechler S J, Lee E, Ahnen D. et al . Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.  JAMA. 2001;  285 2331-2338
• 20 Mason R J, Hughes M, Lehman G A. et al . Endoscopic augmentation of the cardia with a biocompatible injectable polymer (Enteryx) in a porcine model.  Surg Endosc. 2002;  16 386-391
• 21 Sampliner R E. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 1888-1895
• 22 Souza R F, Morales C P, Spechler S J. A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett’s oesophagus.  Aliment Pharmacol Ther. 2001;  15 1087-1100
• 23 Dixon M F, Neville P M, Mapstone N P. et al . Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastro-oesophageal reflux?.  Gut. 2001;  49 359-363
• 24 Tharalson E F, Martinez S D, Garewal H S. et al . Relationship between rate of change in acid exposure along the esophagus and length of Barrett’s epithelium.  Am J Gastroenterol. 2002;  97 851-856
• 25 Zentilin P, Conio M, Mele M R. et al . Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett’s oesophagus.  Aliment Pharmacol Ther. 2002;  16 893-898
• 26 Avidan B, Sonnenberg A, Schnell T G. et al . Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.  Am J Gastroenterol. 2002;  97 1930-1936
• 27 Geddert H, Heep H J, Gabbert H E, Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.  Cancer. 2002;  94 212-218
• 28 Shen B, Ormsby A H, Shen C. et al . Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.  Cancer. 2002;  94 820-831
• 29 Going J J, Keith W N, Neilson L. et al . Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett’s mucosa.  Gut. 2002;  50 373-377
• 30 Rabinovitch P S, Longton G, Blount P L. et al . Predictors of progression in Barrett’s esophagus, 3: baseline flow cytometric variables.  Am J Gastroenterol. 2001;  96 3071-3083
• 31 Rader A E, Faigel D O, Ditomasso J. et al . Cytological screening for Barrett’s esophagus using a prototype flexible mesh catheter.  Dig Dis Sci. 2001;  46 2681-2686
• 32 Scotiniotis I A, Kochman M L, Lewis J D. et al . Accuracy of EUS in the evaluation of Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma.  Gastrointest Endosc. 2001;  54 689-696
• 33 Sonnenberg A, Soni A, Sampliner R E. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma.  Aliment Pharmacol Ther. 2002;  16 41-50
• 34 Buttar N S, Wang K K, Anderson M A. et al . The effect of selective cyclooxygenase-2 inhibition in Barrett’s esophagus epithelium: an in vitro study.  J Natl Cancer Inst. 2002;  94 422-429
• 35 Buttar N S, Wang K K, Leontovich O. et al . Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus.  Gastroenterology. 2002;  122 1101-1112
• 36 Buskens C J, van Rees B P, Sivula A. et al . Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.  Gastroenterology. 2002;  122 1800-1807
• 37 Sampliner R E, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 270-272
• 38 Carlson N, Lechago J, Richter J. et al . Acid suppression therapy may not alter malignant progression in Barrett’s metaplasia showing p53 protein accumulation.  Am J Gastroenterol. 2002;  97 1340-1345
• 39 Javaid B, Watt P, Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study.  Lasers Med Sci. 2002;  17 51-56
• 40 Buttar N S, Wang K K, Lutzke L S. et al . Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus.  Gastrointest Endosc. 2001;  54 682-688